Table of Contents
Hepatitis Research and Treatment
Volume 2017, Article ID 2093847, 7 pages
https://doi.org/10.1155/2017/2093847
Clinical Study

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir

Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama 641-0012, Japan

Correspondence should be addressed to Hideyuki Tamai; pj.ca.dem-amayakaw@edihamat

Received 23 December 2016; Revised 16 February 2017; Accepted 21 February 2017; Published 11 April 2017

Academic Editor: Yoichi Hiasa

Copyright © 2017 Hideyuki Tamai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Yokosuka, K. Takaguchi, S. Fujioka et al., “Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection,” Journal of Hepatology, vol. 52, no. 6, pp. 791–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. European Association for the Study of the Liver, “EASL Clinical Practice Guidelines: management of chronic hepatitis B,” Journal of Hepatology, vol. 50, pp. 227–242, 2009. View at Google Scholar
  4. Y.-F. Liaw, N. Leung, J.-H. Kao et al., “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update,” Hepatology International, vol. 2, no. 3, pp. 263–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology, “JSH guidelines for the management of hepatitis B virus infection,” Hepatology Research, vol. 44, supplement 1, pp. 1–58, 2014. View at Publisher · View at Google Scholar
  6. L. Serfaty, D. Thabut, F. Zoulim et al., “Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study,” Hepatology, vol. 34, no. 3, pp. 573–577, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Chen, Z. Cao, Y. Liu et al., “Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog,” Journal of Gastroenterology and Hepatology (Australia), vol. 27, no. 3, pp. 481–486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Kittner, M. F. Sprinzl, A. Grambihler et al., “Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B,” Journal of Clinical Virology, vol. 54, no. 1, pp. 93–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Tanaka and A. Matsumoto, “Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B,” Hepatology Research, vol. 44, no. 1, pp. 1–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. P. Reijnders, V. Rijckborst, M. J. Sonneveld et al., “Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir,” Journal of Hepatology, vol. 54, no. 3, pp. 449–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-F. Liaw, J.-D. Jia, H. L. Y. Chan et al., “Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C,” Hepatology, vol. 54, no. 5, pp. 1591–1599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Marcellin, G. K. K. Lau, F. Bonino et al., “Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B,” New England Journal of Medicine, vol. 351, no. 12, pp. 1206–1217, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. K. K. Lau, T. Piratvisuth, X. L. Kang et al., “Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B,” New England Journal of Medicine, vol. 352, no. 26, pp. 2682–2695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. Q. Xie, H. Zhou, X. Bai et al., “A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B ‘e’ antigen-positive chronic hepatitis B,” Clinical Infectious Diseases, vol. 59, no. 12, pp. 1714–1723, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology, “Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology,” Hepatology Research, vol. 43, no. 1, pp. 1–34, 2013. View at Publisher · View at Google Scholar
  17. D. Ouzan, G. Pénaranda, H. Joly, H. Khiri, A. Pironti, and P. Halfon, “Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs,” Journal of Clinical Virology, vol. 58, no. 4, pp. 713–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Marcellin, S. H. Ahn, W. Chuang et al., “Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B,” Alimentary Pharmacology & Therapeutics, vol. 44, no. 9, pp. 957–966, 2016. View at Publisher · View at Google Scholar
  19. T. Tseng, C. Liu, H. Yang et al., “High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load,” Gastroenterology, vol. 142, no. 5, pp. 1140.e3–1149.e3, 2012. View at Publisher · View at Google Scholar
  20. W. P. Brouwer, Q. Xie, M. J. Sonneveld et al., “Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study),” Hepatology, vol. 61, no. 5, pp. 1512–1522, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. E. H. C. J. Buster, B. E. Hansen, G. K. K. Lau et al., “Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa,” Gastroenterology, vol. 137, no. 6, pp. 2002–2009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Moucari, V. Mackiewicz, O. Lada et al., “Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients,” Hepatology, vol. 49, no. 4, pp. 1151–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Rijckborst, B. E. Hansen, Y. Cakaloglu et al., “Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels,” Hepatology, vol. 52, no. 2, pp. 454–461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. J. Sonneveld, V. Rijckborst, C. A. B. Boucher, B. E. Hansen, and H. L. A. Janssen, “Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline,” Hepatology, vol. 52, no. 4, pp. 1251–1257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-Y. Peng, H.-C. Lai, Y.-F. Li, W.-P. Su, P.-H. Chuang, and J.-T. Kao, “Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 4, pp. 458–468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-C. Wang, S.-S. Yang, C.-W. Su et al., “Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis,” Scientific Reports, vol. 6, Article ID 29605, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Martinot-Peignoux, M. Lapalus, S. Maylin et al., “Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients,” Journal of Viral Hepatitis, vol. 23, no. 11, pp. 905–911, 2016. View at Publisher · View at Google Scholar
  28. Q. Ning, M. Han, Y. Sun et al., “Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial),” Journal of Hepatology, vol. 61, no. 4, pp. 777–784, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Martinot-Peignoux, M. Lapalus, T. Asselah, and P. Marcellin, “HBsAg quantification: useful for monitoring natural history and treatment outcome,” Liver International, vol. 34, supplement 1, pp. 97–107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Kang and J. Y. Park, “When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7207–7212, 2014. View at Publisher · View at Google Scholar · View at Scopus